Work

Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations

Year: 2019

Type: article

Abstract: Plasma cell myeloma (PCM) is a clonal PC neoplasm that represents the second most common and mostly incurable hematopoietic malignancy comprising ~20% of all hematologic-related cancer deaths in the United States 1 , 2 . The diagnosis of PCM requires evidence of clonal expansion of PCs representing ≥10% of the bone marrow, elevated monoclonal protein concentration in the serum and/or urine, lytic bone lesions, and/or end organ damage 3 , 4 , 5 . Multiple risk stratification systems and prognostic-based therapeutic approaches have been devised incorporating a variety of clinical metrics including host factors such as age, performance status, comorbidities, serum beta-2 microglobulin, albumin, lactate dehydrogenase, and proliferation indices.

Source: Blood Cancer Journal

DOI: 10.1038/s41408-019-0182-z